EGCG (epigallocatechin gallate) whitening composition with barrier repairing effect as well as preparation method and application of EGCG whitening composition

Abstract

The invention relates to an EGCG (epigallocatechin gallate) whitening composition with a barrier repairing effect as well as a preparation method and application of the EGCG whitening composition, and belongs to the technical field of cosmetics. The invention provides an EGCG (epigallocatechin gallate) whitening composition. The EGCG whitening composition is prepared from the following components in parts by mass: 0.1 to 0.5 part of phenylethyl resorcinol, 0.2 to 2.0 parts of orchid fruit leaf extract and 0.1 to 0.5 part of epigallocatechin gallate. The EGCG whitening composition is prepared by matching the phenethyl resorcinol, the orchid fruit leaf extract and the EGCG, and the orchid fruit leaf extract and the EGCG can relieve the irritation of the phenethyl resorcinol, so that the synergistic improvement of whitening and barrier repairing is realized.

Description

Technical Field

[0001] The present invention relates to the technical field of cosmetics, and in particular to an EGCG whitening composition with barrier repairing effect, and a preparation method and application thereof. Background Art

[0002] With the growing demand for skin care from consumers, the cosmetics industry is constantly exploring innovative ingredients and formulas that can simultaneously repair the skin barrier and whiten the skin. Repairing the skin barrier is crucial to maintaining skin health, while whitening effects can improve uneven skin tone and pigmentation. However, in existing cosmetics, ingredients for barrier repair and whitening effects are usually used separately, and commonly used whitening ingredients (such as phenylethyl resorcinol) are often irritating. Products on the market often have good whitening effects, but require tolerance to use and can easily damage the skin barrier. As a result, not only can they not be used on consumers with sensitive skin or damaged skin barriers, but they can also worsen the condition of originally healthy skin.

[0003] Therefore, developing a composition that has high whitening efficacy and can repair the skin barrier is a research hotspot in the cosmetics field and is also an urgent need of current consumers, who hope to achieve safe and efficient whitening and beauty. Summary of the Invention

[0004] The purpose of the present invention is to overcome the shortcomings of the prior art and provide an EGCG whitening composition with the effect of repairing the skin barrier, as well as a preparation method and application thereof.

[0005] To achieve the above object, the technical solution adopted by the present invention is:

[0006] In a first aspect, the present invention provides an EGCG whitening composition with barrier repairing effect, comprising the following components in parts by weight: 0.1-0.5 parts of phenylethylresorcinol, 0.2-2.0 parts of lansatilla leaf extract and 0.1-0.5 parts of epigallocatechin gallate.

[0007] Phenylethyl resorcinol (commonly known as 377) is a cosmetic raw material with significant whitening effects. However, this raw material is highly irritating. If added in high concentrations, users need to build up tolerance before achieving daily whitening effects. Moreover, people with sensitive skin find it difficult to build up tolerance to normally use cosmetics containing this raw material.

[0008] Laium domesticum leaf extract is a natural product extracted from the leaves of Laium domesticum. It is relatively safe and has certain whitening effects.

[0009] Epigallocatechin gallate (EGCG) is the ingredient with the strongest antioxidant activity among tea polyphenols. It is extracted from natural plants such as tea leaves and is relatively safe, meeting consumers' demand for natural cosmetic ingredients. It can scavenge various free radicals, absorb some ultraviolet rays, and reduce the damage of ultraviolet rays to the skin. At the same time, it can reduce ultraviolet-induced oxidative damage and inflammatory reactions through antioxidant effects.

[0010] The present invention combines phenylethylresorcinol, lansatilla leaf extract and EGCG to form an EGCG whitening composition. The lansatilla leaf extract and EGCG can alleviate the irritation of phenylethylresorcinol and achieve synergistic improvement of whitening and barrier repair.

[0011] As a preferred embodiment of the EGCG whitening composition of the present invention, it includes the following components in parts by weight: 0.15-0.3 parts of phenylethylresorcinol, 0.5-1.0 parts of lansatilla leaf extract, and 0.15-0.3 parts of epigallocatechin gallate. Within the preferred mass ratio range, the present invention has experimentally confirmed that the EGCG whitening composition within a specific mass ratio range has excellent whitening and barrier repair effects.

[0012] As a preferred embodiment of the EGCG whitening composition of the present invention, it includes the following components by weight: 0.3 parts of phenylethylresorcinol, 1.0 parts of lansatilla leaf extract, and 0.3 parts of epigallocatechin gallate. The present invention has experimentally confirmed that the EGCG whitening composition within a specific weight range has excellent whitening and barrier repair effects.

[0013] As a preferred embodiment of the EGCG whitening composition of the present invention, it includes the following components by weight: 0.5 parts of phenylethylresorcinol, 2.0 parts of lansatilla leaf extract, and 0.5 parts of epigallocatechin gallate. The present invention has experimentally confirmed that the EGCG whitening composition within a specific weight range has the best whitening and barrier repair effects.

[0014] As a preferred embodiment of the EGCG whitening composition of the present invention, the mass ratio of the sum of phenethylresorcinol and epigallocatechin gallate to lansatilla fruit leaf extract is (phenethylresorcinol + epigallocatechin gallate): lansatilla fruit leaf extract = (0.1-2): 1. The present invention has found through experiments that the sum of phenethylresorcinol and epigallocatechin gallate and lansatilla fruit leaf extract can achieve better whitening and barrier repair effects within a specific ratio range.

[0015] As a preferred embodiment of the EGCG whitening composition of the present invention, the mass ratio of the sum of phenethylresorcinol and epigallocatechin gallate to the lansatilla fruit leaf extract is (phenethylresorcinol + epigallocatechin gallate): lansatilla fruit leaf extract = (0.1-1): 1. The present invention has found through experiments that the sum of phenethylresorcinol and epigallocatechin gallate and lansatilla fruit leaf extract can further enhance the whitening and barrier repair efficacy of the EGCG whitening composition within a specific ratio range.

[0016] As a preferred embodiment of the EGCG whitening composition of the present invention, the mass ratio of the sum of phenethylresorcinol and epigallocatechin gallate to the lansatilla fruit leaf extract is (phenethylresorcinol+epigallocatechin gallate):lansatilla fruit leaf extract=0.5:1.

[0017] In a second aspect, the present invention provides a method for preparing the above-mentioned EGCG whitening composition, wherein phenylethylresorcinol, lansatilla leaf extract and epigallocatechin gallate are mixed at 50-70° C. to obtain the EGCG whitening composition.

[0018] In a third aspect, the present invention provides the use of the above-mentioned EGCG whitening composition in the preparation of cosmetics.

[0019] The present invention verifies through experiments that the EGCG whitening composition has excellent whitening and skin barrier repairing effects and can be used in various types of cosmetics.

[0020] As a preferred embodiment of the application of the present invention, the dosage form of the cosmetic includes at least one of creams, emulsions, aqueous solutions, gels, oils, powders, block powders or solids, patches, films and freeze-dried products.

[0021] In a fourth aspect, the present invention provides an emulsion with barrier repair and whitening effects, the emulsion comprising 0.5-3 parts by mass of the above-mentioned EGCG whitening composition, 2-4 parts by mass of a stabilizer, 0.4-0.6 parts by mass of a preservative, 65-85 parts by mass of water, 0.7-1.5 parts by mass of an emulsifier, and 9.85-18.2 parts by mass of a moisturizer; the emulsifier comprises emulsifier A and emulsifier B, and the moisturizer comprises an aqueous moisturizer and an oily moisturizer;

[0022] The emulsifier A in the emulsion includes at least one of polysorbate 80, Span 80, and Span 85, and the emulsifier B in the emulsion includes triethanolamine and / or fatty alcohol polyoxyethylene ether. The present invention has experimentally confirmed that the EGCG whitening composition not only has excellent whitening and skin barrier repair effects, but also has a certain degree of stability. Its application in emulsion cosmetics can improve the stability of the emulsion and reduce the yellowing phenomenon of phenylethylresorcinol during formulation application.

[0023] As a preferred embodiment of the emulsion of the present invention, the emulsion includes 1.25 parts by mass of the above-mentioned EGCG whitening composition, 3 parts by mass of a stabilizer, 0.5 parts by mass of a preservative, 65-85 parts by mass of water, 13.7 parts by mass of an emulsifier and 1.1 parts by mass of a moisturizer.

[0024] As a preferred embodiment of the emulsion of the present invention, the stabilizer in the emulsion includes caprylic / capric triglyceride and / or tocopheryl acetate.

[0025] As a preferred embodiment of the emulsion of the present invention, the preservative in the emulsion includes at least one of phenoxyethanol, methylparaben and sorbic acid.

[0026] As a preferred embodiment of the emulsion of the present invention, the oily moisturizer in the emulsion includes at least one of isononyl isononanoate, jojoba oil and lecithin, and the aqueous moisturizer in the emulsion includes at least one of glycerin, 1,3-butylene glycol and allantoin.

[0027] As a preferred embodiment of the emulsion of the present invention, the emulsifier A in the emulsion contains polysorbate 80, the emulsifier B in the emulsion contains triethanolamine, and the mass ratio of polysorbate 80 to triethanolamine is polysorbate 80:triethanolamine = (0.5-1.0): (0.2-0.5).

[0028] As a preferred embodiment of the emulsion of the present invention, the mass ratio of polysorbate 80 to triethanolamine is polysorbate 80:triethanolamine=0.8:0.3.

[0029] As a preferred embodiment of the emulsion of the present invention, the oily moisturizer in the emulsion includes 2.0-4.0 parts by mass of isononyl isononanoate, 1.5-3.0 parts by mass of jojoba oil and 0.2-0.8 parts by mass of lecithin, and the aqueous moisturizer in the emulsion includes 4.0-6.0 parts by mass of glycerin, 2.0-4.0 parts by mass of 1,3-butylene glycol and 0.15-0.4 parts by mass of allantoin.

[0030] As a preferred embodiment of the emulsion of the present invention, the oily moisturizer in the emulsion includes 3.0 parts by mass of isononyl isononanoate, 2.0 parts by mass of jojoba oil and 0.5 parts by mass of lecithin, and the aqueous moisturizer in the emulsion includes 5.0 parts by mass of glycerin, 3.0 parts by mass of 1,3-butylene glycol and 0.2 parts by mass of allantoin.

[0031] As a preferred embodiment of the emulsion of the present invention, the emulsion further comprises 0.1 parts by mass of essence.

[0032] In a fifth aspect, the present invention provides a method for preparing the above-mentioned emulsion, comprising the following steps:

[0033] (1) mixing an oily moisturizer, an emulsifier B, and a stabilizer at 75-80° C. to obtain an oil phase;

[0034] (2) mixing an aqueous moisturizer and water at 23-27° C. to obtain an aqueous phase;

[0035] (3) adding the aqueous phase obtained in step (2) to the oil phase obtained in step (1), homogenizing at 75-80° C. for 10-15 min, and adding emulsifier B when the temperature drops to 50-55° C. to obtain a mixed solution;

[0036] (4) When the mixed solution obtained in step (3) is cooled to 40-50° C., the above-mentioned EGCG whitening composition is added. When the temperature drops to 30-40° C., a preservative is added, mixed evenly, and cooled to 23-27° C. to obtain an emulsion.

[0037] As a preferred embodiment of the preparation method of the present invention, in step (4), the EGCG whitening composition is in liquid form.

[0038] As a preferred embodiment of the preparation method of the present invention, when the emulsion contains essence, step (4) is performed as follows:

[0039] (4) When the mixed solution obtained in step (3) is cooled to 30-40° C., a preservative and a flavor are added, mixed evenly, and cooled to 23-27° C. to obtain an emulsion.

[0040] Compared with the prior art, the present invention has the following beneficial effects:

[0041] (1) The present invention utilizes the antioxidant properties of EGCG, combines Lansaria officinalis leaf extract and phenylethylresorcinol to form an EGCG whitening composition, which can reduce the irritation of phenylethylresorcinol while maintaining excellent whitening performance, thereby achieving a synergistic improvement in the dual performance of whitening and barrier repair.

[0042] (2) The present invention prepares cosmetics with whitening and barrier repair effects by combining the EGCG whitening composition with other cosmetic excipients (such as moisturizers, emulsifiers, stabilizers, preservatives, etc.). It is found that in addition to having excellent whitening and barrier repair effects, the EGCG whitening composition can also improve the stability of cosmetics and reduce the yellowing phenomenon of phenylethylresorcinol in the formulation application. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 This is a graph showing the tyrosinase inhibition rate test results of different emulsions in Example 1 of the present invention;

[0044] Figure 2 This is a morphological diagram of the emulsion obtained in Example 9 of Effect Example 2 of the present invention. DETAILED DESCRIPTION

[0045] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0046] Unless otherwise specified, other materials, reagents, etc. used in the Examples, Comparative Examples, and Effect Examples can be obtained from commercial sources.

[0047] The Lansa fruit leaf extract in the following examples and comparative examples was purchased from Foshan Xinan Chemical Trading Co., Ltd. under the trade name

[0048] 0.05mol / L PBS (pH=6.8) was prepared by mixing 50mL of solution A and 50mL of solution B. Solution A was a 0.05mol / L Na2HPO4 solution, and solution B was a 0.05mol / L KH2PO4 solution.

[0049] The tyrosinase solution is a 100 U / mL tyrosinase PBS solution, and the PBS is 0.05 mol / L PBS (pH=6.8), which is prepared before use.

[0050] The levodopa solution was a 1 mg / mL levodopa PBS solution, and the PBS was 0.05 mol / L PBS (pH=6.8), which was stored in the dark.

[0051] Examples 1-6 and Comparative Examples 1-4

[0052] Examples 1-6 and Comparative Examples 1-4 respectively provide an EGCG whitening composition with barrier repair efficacy and a preparation method thereof. The components and amounts of the EGCG whitening composition are shown in Table 1. The preparation method comprises mixing phenylethylresorcinol, lansatilla leaf extract and epigallocatechin gallate at 75-80° C. to obtain the EGCG whitening composition.

[0053] Table 1 Components and dosages of different EGCG whitening compositions (parts by mass)

[0054]

[0055]

[0056] Comparative Example 5

[0057] Comparative Example 5 provides an EGCG whitening composition with barrier repair effect and a preparation method thereof. The components and amounts of the EGCG whitening composition are similar to those of Example 1, except that phenylethylresorcinol is replaced by arbutin, and the other components and amounts remain unchanged. The preparation method is the same as that of Example 1.

[0058] Comparative Example 6

[0059] Comparative Example 6 provides an EGCG whitening composition with barrier repair effect and a preparation method thereof. The components and amounts of the EGCG whitening composition are similar to those of Example 1, except that EGCG is replaced by glycyrrhizin, and the other components and amounts remain unchanged.

[0060] Examples 7-11 and Comparative Examples 7-8

[0061] Examples 7-11 and Comparative Examples 7-8 respectively provide an emulsion with barrier repair and whitening effects and a preparation method thereof. The components and amounts of the emulsion are shown in Table 2. The preparation method comprises the following steps:

[0062] (1) mixing an oily moisturizer, an emulsifier A, and a stabilizer at 76-82° C. to obtain an oil phase;

[0063] (2) mixing an aqueous moisturizer and water at 23-27° C. to obtain an aqueous phase;

[0064] (3) adding the aqueous phase obtained in step (2) to the oil phase obtained in step (1), homogenizing at 75-80° C. for 10-15 min, and adding emulsifier B when the temperature drops to 50-55° C. to obtain a mixed solution;

[0065] (4) When the mixed solution obtained in step (3) is cooled to 45-50° C., the EGCG whitening composition is added. When the temperature is cooled to 30-40° C., a preservative and a flavor are added, mixed evenly, and cooled to 23-27° C. to obtain an emulsion.

[0066] Table 2 Components and dosage of different emulsions (parts by mass)

[0067]

[0068] Comparative Example 9

[0069] Comparative Example 9 provides an emulsion with barrier repair and whitening effects and a preparation method thereof. The components and amounts of the emulsion are similar to those of Example 7, except that the EGCG whitening composition in the emulsion obtained in Example 7 is replaced by the EGCG whitening composition obtained in Comparative Example 5. The remaining components and amounts remain unchanged, and the preparation method is the same as that of Example 7.

[0070] Effect Example 1

[0071] The EGCG whitening compositions obtained in Examples 1-6 and Comparative Examples 1-6 were tested for their whitening and barrier repair efficacy. The specific protocol is as follows:

[0072] 1. Whitening effect.

[0073] The test solution was prepared according to Table 3. The test sample, 0.05 M PBS buffer (pH 6.8), and tyrosinase solution were added to the test tube in sequence. The test tube was placed in a 37°C water bath for 10 minutes. Then, 2 mL of DOPA solution was added. After reacting for 5 minutes, the absorbance was measured at 475 nm. The absolute difference between two independent determination results obtained under repeatability conditions should not exceed 10% of the arithmetic mean. The tyrosinase inhibition rate (%) was calculated according to formula (1). The results are shown in Tables 4 and Figure 1 .

[0074] Table 3 Reaction solution composition (mL)

[0075]

[0076] Tyrosinase inhibition rate (%) = [1-(OD C -OD D ) / (OD A -OD B )]×100%——Formula (1)

[0077] In the above formula, OD A is the absorbance value of the enzyme solution control group; OD B is the absorbance value of the enzyme solution blank group; OD C is the absorbance value of the sample group; OD D is the absorbance value of the blank control of the sample group.

[0078] Table 4 Tyrosinase inhibition rate test results of different EGCG whitening compositions

[0079]

[0080]

[0081] From Table 4 and Figure 1As shown, the tyrosinase inhibition rates of the examples are all higher than those of the comparative examples, indicating that the EGCG whitening composition of the present invention has relatively excellent whitening efficacy, among which the tyrosinase inhibition rate of Example 2 is the highest, indicating that the EGCG whitening composition of Example 2 has the best whitening efficacy.

[0082] It can be seen from Examples 1-5 that as the amount of phenethylresorcinol and EGCG increases, the tyrosinase inhibition rate of the EGCG whitening composition also increases. However, when the mass ratio of phenethylresorcinol and EGCG to the Lansago leaf extract exceeds 2:1, the tyrosinase inhibition rate of the EGCG whitening composition shows a downward trend. This indicates that when the mass ratio of phenethylresorcinol and EGCG to the Lansago leaf extract is (0.1-2):1, the tyrosinase inhibition effect of the EGCG whitening composition is more prominent.

[0083] Compared with Comparative Examples 1-3, the tyrosinase inhibition rates of Example 2 and Comparative Examples 1-3 are lower than those of Example 2, and the sum of the tyrosinase inhibition rates of Comparative Examples 1-3 (66.85%) is less than that of Example 2. The tyrosinase inhibition rates of Example 2 are all higher than those of Comparative Examples 4-6. If the mass ratio of phenethylresorcinol and EGCG to the lansa fruit leaf extract is not within the range of (0.1-3): 1, the tyrosinase inhibition rate of the EGCG whitening composition will decrease. If phenethylresorcinol or EGCG is replaced with a similar active ingredient, the lansa fruit leaf extract cannot synergize with the active ingredient, indicating that only by combining phenethylresorcinol, EGCG and lansa fruit leaf extract into an EGCG whitening composition can the synergistic whitening effect be achieved, and the mass ratio of phenethylresorcinol and EGCG to the lansa fruit leaf extract must be (0.1-3): 1 to achieve a better whitening effect.

[0084] 2. Repair performance test

[0085] Cell migration assay

[0086] Experimental principle:

[0087] The ability of cell migration directly reflects the activity level of cells. If cells can proliferate and migrate rapidly, they can form a protective mechanism as quickly as possible in response to exogenous stimuli, thereby repairing damaged cells. The cell scratch (repair) method is a simple method to measure cell migration and repair ability. It is similar to the in vitro wound healing model. On a monolayer of adherent cells cultured in an in vitro culture dish or plate, a line is drawn in the central area of cell growth with a micropipette tip or other hard object, and the cells in the central part are removed. The cells are then cultured for the time set in the experiment. The cell culture plate is then removed to observe whether the surrounding cells grow (repair) to the central scratch area. This is used to judge the repair ability of the cells. The experiment usually requires setting up a normal control group and an experimental group. The experimental group is a group to which certain treatment factors, drugs, exogenous genes, etc. are added. The ability of cells in different groups to repair the scratch area can be used to judge the migration and repair ability of each group of cells.

[0088] Samples: (1) Negative control: DMEM culture medium containing 10% serum; (2) Sample group: EGCG whitening composition of Examples 1-6, EGCG whitening composition of Comparative Examples 1-6, using DMEM culture medium containing 10% serum as solvent, prepared into a solution with a mass percentage of 2%; (3) Positive control: using DMEM culture medium containing 10% serum as solvent, prepared into a solution with a mass percentage of 10% epidermal growth factor (EGF).

[0089] Experimental Procedure: HaCaT human keratinocytes were seeded in 12-well plates (100,000 cells / well) and cultured in an incubator at 37°C for 24 hours. After incubation, the original culture medium was discarded, and two scratches were made in each well using a pipette tip. 100 μL of DMEM medium containing 1% serum was added to the negative control, 100 μL of the prepared sample solution was added to each well of the sample group, and 100 μL of a 1% EGF solution was added to each well of the positive control. The cells were incubated for 18 hours. Samples were collected at time points 0 and 18 hours, photographed, and three randomly selected areas were used to calculate the mean scratch area between cells.

[0090] The cell migration rate (wound healing rate) was calculated by the average of the scratch area between cells at 0 h and 18 h. The repair effect of the sample was expressed by the cell migration rate (wound healing rate). The larger the cell migration rate (wound healing rate), the better the repair effect.

[0091] Cell migration rate (wound healing rate) % = (0h scratch area - 18h scratch area) / 0h scratch area

[0092] The results are shown in Table 5.

[0093] Table 5 Cell repair test results of different EGCG whitening compositions

[0094]

[0095]

[0096] As shown in Table 5, the EGCG compositions of Examples 1-6 all have good cell repair capabilities, among which Example 1 has the best effect, indicating that with the addition of lansatilla leaf extract, a good repair effect can be achieved without a high concentration of EGCG. As the lansatilla leaf extract decreases, the cell repair ability will decrease.

[0097] Compared with the examples, the sum of the cell migration rates of comparative examples 1-3 is 51.14%, which is lower than the cell migration rate of the examples. This shows that the EGCG composition of the present invention is not a simple superposition of phenethyl interpolymer, EGCG and lansatilla leaf extract. The combination of the three has a synergistic effect in improving the repair effect.

[0098] Effect Example 2

[0099] The emulsions obtained in Examples 7-11 and Comparative Examples 7-9 were subjected to stability tests. The emulsions were placed at room temperature (25±2°C) and high temperature (45°C) for 45 days. The emulsion states were observed and photographed at 7 days and 45 days, and the state of the emulsions was recorded. The state of Example 9 at room temperature was shown in FIG. Figure 2 , and the rest of the results are shown in Table 6.

[0100] Table 6 Stability test results of different emulsions

[0101]

[0102]

[0103] like Figure 2 As shown in Table 6, the emulsion of Example 9 is white or milky white and has a viscous texture. As shown in Table 6, the emulsions of the examples are more stable. After being stored at a high temperature for 45 days, only a slight yellowing phenomenon occurs, and the emulsion texture is stable. However, the emulsions of Comparative Examples 8-9 show a deeper yellow color after being stored at room temperature for 45 days, and a thinning texture after being stored at a high temperature for 45 days. This indicates that the use of an excessive amount of the EGCG whitening composition or the replacement with the EGCG whitening composition obtained in Comparative Example 5 will affect the stability of the emulsion.

[0104] Effect Example 3

[0105] The emulsions obtained in Examples 7-11 and Comparative Examples 7-9 were tested for whitening and barrier repair efficacy, and the specific scheme is as follows:

[0106] 1. Whitening effect.

[0107] The whitening effect test method in Example 1 was used for testing. The results are shown in Table 7.

[0108] Table 7 Tyrosinase inhibition rate test results of different emulsions

[0109] Group Tyrosinase inhibition rate (%) Example 7 74.34±2.56 Example 8 68.35±3.68 Example 9 78.45±2.76 Example 10 72.56±1.34 Example 11 69.45±4.27 Comparative Example 7 11.31±2.45 Comparative Example 8 43.23±1.46 Comparative Example 9 41.31±3.83

[0110] As shown in Table 7, the emulsions of the examples all have good tyrosinase inhibition rates, among which Example 9 has the highest tyrosinase inhibition rate, indicating that the EGCG whitening composition of the present invention has good whitening efficacy when used in cosmetics. The tyrosinase inhibition rate of Example 9 is better than that of Comparative Examples 7-9, indicating that if the EGCG whitening composition is not added, the amount of the EGCG whitening composition is not appropriate, or the EGCG whitening composition with poor whitening efficacy is used in cosmetics, a good whitening effect cannot be achieved.

[0111] 2. Repair barrier function.

[0112] 40 volunteers were recruited and divided into 8 groups, with 5 people in each group. The emulsions obtained in Examples 7-11 and Comparative Examples 7-9 were used respectively, and the transepidermal water loss (TEWL) of the volunteers' skin was tested using a TewameterR™ 300 skin water loss tester.

[0113] The screening criteria for volunteers include: healthy women, aged 30-60 years old, sensitive skin (positive lactic acid stinging reaction), dry and red facial skin, poor skin barrier function in the test area (TEWL ≥ 15g / m 2 / h), be able to read and understand all the contents of the informed consent form, voluntarily sign the informed consent form, agree not to use any cosmetics, drugs and health products that may affect the results during the trial, will not participate in clinical trials of any other research centers now or during the trial, and has not participated in other clinical studies in the past month.

[0114] Ensure that the volunteers have not used antihistamines in the past week or immunosuppressants in the past month, have not used any anti-inflammatory drugs in the test area in the past two months, do not suffer from inflammatory skin diseases or have inflammatory skin diseases but have been clinically cured, do not suffer from other chronic respiratory diseases such as diabetes or asthma, are not in the lactation, pregnancy or family planning period, have not undergone bilateral mastectomy or bilateral axillary lymph node resection, have not received anti-cancer chemotherapy in the past 6 months, are not allergic, have allergic dermatitis, are not undergoing dermatological treatment, have not taken hydroxy acids, whitening and anti-aging drugs in the past month, and there are no large-area birthmarks, scratches, white spots, pigmented moles, keloids and other skin manifestations that affect the test in the test area.

[0115] During the test, volunteers should pay attention to the following matters: maintain the same living and eating habits as before participating in the test, prohibit the treatment of the tested area that may affect the test, prohibit the use of other skin care products and other products that may affect the test during the test, and daily necessities must be consistent with those used before the start of the test and are prohibited from being replaced.

[0116] Before using the sample, the volunteers' TEWL values were tested (this value was recorded as W0). Each time, the volunteers took 1-2g of the sample and applied it evenly to their faces, gently massaging for absorption. This was done once a day. After four weeks of continuous use, their TEWL values were tested (this value was recorded as W4). Before testing the TEWL value, the volunteers needed to cleanse their faces with clean water and sit quietly in a constant temperature and humidity environment for 30 minutes before starting the test. The TEWL test results are shown in Table 8.

[0117] Table 8 TEWL test results of different emulsions

[0118]

[0119]

[0120] As shown in Table 8, the emulsions obtained in the examples had a high TEWL change rate, with Example 9 having the highest change rate, indicating that the EGCG whitening composition of the present invention has a good barrier repair effect when used in cosmetics. The TEWL change rate of Example 9 is better than that of Comparative Examples 7-9, indicating that if the EGCG whitening composition is not added, the EGCG whitening composition is used in an inappropriate amount, or the EGCG whitening composition has poor barrier repair effect, it will not achieve a good barrier repair effect when used in cosmetics.

[0121] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. An EGCG whitening composition with barrier repair effect, characterized in that: The invention comprises the following components in parts by mass: 0.1-0.5 parts of phenylethylresorcinol, 0.2-2.0 parts of lansatilla fruit leaf extract and 0.1-0.5 parts of epigallocatechin gallate.

2. The EGCG whitening composition according to claim 1, wherein The mass ratio of the sum of phenethyl resorcinol and epigallocatechin gallate to the lansatilla fruit leaf extract is (phenethyl resorcinol+epigallocatechin gallate):lansatilla fruit leaf extract=(0.1-2):

1.

3. The EGCG whitening composition according to claim 2, wherein The mass ratio of the sum of phenethyl resorcinol and epigallocatechin gallate to the lansatilla fruit leaf extract is (phenethyl resorcinol+epigallocatechin gallate):lansatilla fruit leaf extract=(0.1-1):

1.

4. The preparation method of the EGCG whitening composition according to any one of claims 1 to 3, wherein Phenethylresorcinol, Lansaria officinalis leaf extract and epigallocatechin gallate are mixed at 75-80° C. to obtain an EGCG whitening composition.

5. The EGCG whitening composition according to any one of claims 1 to 3 is used in the preparation of cosmetics.

6. The use according to claim 5, characterized in that The dosage form of the cosmetics includes at least one of creams, emulsions, aqueous solutions, gels, oils, powders, block powders or solids, patches, films and freeze-dried products.

7. An emulsion with barrier repair and whitening effects, characterized in that: The emulsion comprises 0.3-3 parts by mass of the EGCG whitening composition according to any one of claims 1-3, 2-4 parts by mass of a stabilizer, 0.4-0.6 parts by mass of a preservative, 65-85 parts by mass of water, 0.7-1.5 parts by mass of an emulsifier, and 9.85-18.2 parts by mass of a moisturizer; the emulsifier comprises emulsifier A and emulsifier B, and the moisturizer comprises an aqueous moisturizer and an oily moisturizer; The emulsifier A in the emulsion includes at least one of polysorbate 80, Span 80 and Span 85, and the emulsifier B in the emulsion includes triethanolamine and / or fatty alcohol polyoxyethylene ether.

8. The emulsion according to claim 7, wherein Including at least one of the following (I) to (III): (I) The stabilizer in the emulsion includes caprylic / capric triglyceride and / or tocopheryl acetate; (II) the preservative in the emulsion includes at least one of phenoxyethanol, methylparaben and sorbic acid; (III) The oily moisturizing agent in the emulsion includes at least one of isononyl isononanoate, jojoba oil and lecithin, and the aqueous moisturizing agent in the emulsion includes at least one of glycerin, 1,3-butylene glycol and allantoin.

9. The emulsion according to claim 8, wherein Including at least one of the following (IV) to (V): (IV) the emulsifier A in the emulsion contains polysorbate 80, the emulsifier B in the emulsion contains triethanolamine, and the mass ratio of polysorbate 80 to triethanolamine is polysorbate 80:triethanolamine = (0.5-1.0): (0.2-0.5); (V) The oily moisturizing agent in the emulsion includes 2.0-4.0 parts by mass of isononyl isononanoate, 1.5-3.0 parts by mass of jojoba oil and 0.2-0.8 parts by mass of lecithin, and the aqueous moisturizing agent in the emulsion includes 4.0-6.0 parts by mass of glycerin, 2.0-4.0 parts by mass of 1,3-butylene glycol and 0.15-0.4 parts by mass of allantoin.

10. The method for preparing the emulsion according to any one of claims 7 to 9, characterized in that: The following steps are involved: (1) mixing an oily moisturizer, an emulsifier A, and a stabilizer at 75-80° C. to obtain an oil phase; (2) mixing an aqueous moisturizer and water at 23-27° C. to obtain an aqueous phase; (3) adding the aqueous phase obtained in step (2) to the oil phase obtained in step (1), homogenizing at 75-80° C. for 10-15 min, and adding emulsifier B when the temperature drops to 50-55° C. to obtain a mixed solution; (4) When the mixed solution obtained in step (3) is cooled to 45-50°C, the EGCG whitening composition according to any one of claims 1-3 is added. When the temperature is cooled to 30-40°C, a preservative is added, mixed evenly, and cooled to 23-27°C to obtain an emulsion.

Images